Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The awards carry an exercise price equal to the grant-date closing share price and vest subject to continued employee service.

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) awarded inducement stock options to two new employees on October 1, 2026, covering 207,150 common shares. The options have an exercise price of $18.20 per share, equal to the Nasdaq closing price on the grant date.

One-fourth vest on the first anniversary of each employee’s applicable start date; the remainder vest in 12 equal quarterly installments, subject to continued service through each vesting date. The awards were granted under the 2026 Inducement Plan, outside stockholder-approved equity incentive plans, as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

Positive

• Minor pointTwo new employees received equity awards as a material inducement to employment.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options for 207,150 shares at $18.20 per share create potential dilution if exercised.

Argus 15 min delay 2 alerts

-1.96% vs previous close $17.29 last price 1.1x rel. volume Open Argus

Details

Market Reaction – BCAX

+4.3% Peak Tracked

$17.11 – $19.12 Day Range

$1.14B Market Cap

On Oct 5, the day this news came out, the latest delayed price for BCAX is 1.96% below the previous close. Argus tracked a peak move of +4.3% during the session. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $17.29.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Options granted: 207,150 shares Exercise price: $18.20 per share Initial vesting: One-fourth +1 more

Options granted

207,150 shares

Aggregate award to two new employees

Exercise price

$18.20 per share

Equal to the Nasdaq closing price on October 1, 2026

Initial vesting

One-fourth

Vests on the first anniversary of the applicable employee start date

Remaining vesting

12 equal quarterly installments

After initial vesting, subject to continued service

Historical Context

2 past events · Latest: Sep 03

2 events

1. Sep 03

   Inducement grants

   24h Move

   -0.9%

   Two employees received options under the same 2026 Inducement Plan with a comparable vesting schedule.

2. Aug 14

   Inducement grant

   24h Move

   +2.8%

   A new CFO received options under the 2026 Inducement Plan with a comparable vesting schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, par value, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"non-qualified stock options to purchase 207,150 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

par value financial

"common stock, par value $0.0001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on October 1, 2026 to two new employees as a material inducement to employment under Bicara’s 2026 Inducement Plan.

The employees received, in the aggregate, non-qualified stock options to purchase 207,150 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $18.20 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on October 1, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.

All of the above-described awards were granted outside of Bicara’s stockholder-approved equity incentive plans and are pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The awards were approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Tim Palmer
Tim.Palmer@bicara.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do Bicara Therapeutics’ October 2026 inducement options vest?

One-fourth of the options vest on the first anniversary of each employee’s applicable start date, with the remainder vesting in 12 equal quarterly installments thereafter. Each vesting installment requires continued service with Bicara through the applicable vesting date.

Who approved Bicara Therapeutics’ October 2026 inducement grants?

The grants were approved by Bicara’s compensation committee, which consists solely of independent directors. The board adopted the 2026 Inducement Plan in January 2026, and the awards were granted outside stockholder-approved equity incentive plans under Nasdaq Listing Rule 5635(c)(4).